These genotypes lead to more severe disease (earlier onset, more frequent attacks, and higher risk of amyloidosis) [16–18] and therefore may increase the need for anti-IL-1 agents in this population as described in a previous study [19]. The gene discussed is IL1B; the disease is amyloidosis.